Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TAR-200 alone or in combination with cetrelimab, and cetrelimab alone, in non-muscle invasive bladder cancer unresponsive to BCG and in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Cetrelimab
• TAR-200

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Urinary Bladder Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING